676371-00-9

Usage

Uses

Used in Pharmaceutical Industry:
6-Bromo-imidazo[1,2-a]pyridin-8-amine is used as a key intermediate in the synthesis of various drugs and biologically active compounds. Its unique structure and functional groups allow for the development of new pharmaceutical agents with potential therapeutic applications.
Used in Chemical Industry:
In the chemical industry, 6-Bromo-imidazo[1,2-a]pyridin-8-amine serves as a versatile building block for the creation of a wide range of organic compounds. Its reactivity and compatibility with various chemical reactions make it a valuable component in the synthesis of complex molecules and materials.
Used in Medicinal Chemistry:
6-Bromo-imidazo[1,2-a]pyridin-8-amine is utilized in medicinal chemistry for the design and development of novel therapeutic agents. Its presence in various drug candidates highlights its potential role in modulating biological targets and pathways, contributing to the discovery of new treatments for various diseases and conditions.

InChI:InChI=1/C8H5BrN2O2/c9-5-3-6(8(12)13)7-10-1-2-11(7)4-5/h1-4H,(H,12,13)

Upstream product

• 107-20-0 2-chloroethanal 
• 38875-53-5 5-bromo-pyridine-2,3-diamine 
• 2032-35-1 Bromoacetaldehyde diethyl acetal 
• 17157-48-1 bromoacetaldehyde 

Downstream Products

• 1161846-73-6 N-[3-(8-aminoimidazo[1,2-a]pyridin-6-yl)-2-methylphenyl]-4-tert-butylbenzamide 
• 1161847-43-3 pyrrolidine-1-carboxylic acid [3-(8-aminoimidazo[1,2-a]pyridin-6-yl)-2-methylphenyl]amide 
• 1160994-94-4 8-aminoimidazo[1,2-a]pyridine-6-carboxylic acid methyl ester 
• 1402595-20-3 tert-butyl {6-bromo-3-[4-(cyclopropylcarbamoyl)-3-methylphenyl]imidazo[1,2-a]pyridin-8-yl}(3,3,3-trifluoropropyl)carbamate 
• 1402593-38-7 N-cyclopropyl-4-{6-(2-fluoro-4-methoxyphenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-a]pyridin-3-yl}-2-methylbenzamide 
• 1402593-37-6 N-cyclopropyl-4-{6-(3-fluorophenoxy)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-a]pyridin-3-yl}-2-methylbenzamide 
• 1402593-36-5 C₂₂H₂₃F₃N₄O₃S 
• 1402593-35-4 N-cyclopropyl-2-methyl-4-{6-(methylsulfanyl)-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-a]pyridin-3-yl}benzamide 
• 1402593-29-6 N-cyclopropyl-4-{6-[(3-fluoro-5-methylphenyl)sulfanyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-a]pyridin-3-yl}-2-methylbenzamide 
• 1402593-27-4 N-cyclopropyl-4-{6-[2-(hydroxymethyl)phenyl]-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-a]pyridin-3-yl}-2-methylbenzamide 
• 1402596-16-0 tert-butyl {6-bromo-3-[4-(cyclopropylcarbamoyl)-3-methylphenyl]imidazo[1,2-a]pyridin-8-yl}(2,2-difluoroethyl)carbamate 
• 1402596-15-9 tert-butyl {3-[4-(cyclopropylcarbamoyl)-3-methylphenyl]-6-(3-fluorophenoxy)imidazo[1,2-a]pyridin-8-yl}(2,2-difluoroethyl)carbamate 
• 1402594-95-9 N-cyclopropyl-4-{8-[(2,2-difluoroethyl)amino]-6-(3-fluorophenoxy)imidazo[1,2-a]pyridin-3-yl}-2-methylbenzamide 
• 1402595-17-8 4-{6-bromo-8-[(3,3,3-trifluoropropyl)amino]imidazo[1,2-a]pyridin-3-yl}-N-cyclopropyl-2-methylbenzamide 

Relevant academic research and scientific papers

From Synthetic Simplified Marine Metabolite Analogues to New Selective Allosteric Inhibitor of Aurora B Kinase

Significant inhibition of Aurora B was achieved by the synthesis of simplified fragments of benzosceptrins and oroidin belonging to the marine pyrrole-2-aminoimidazoles metabolites isolated from sponges. Evaluation of kinase inhibition enabled the discovery of a synthetically accessible rigid acetylenic structural analogue EL-228 (1), whose structure could be optimized into the potent CJ2-150 (37). Here we present the synthesis of new inhibitors of Aurora B kinase, which is an important target for cancer therapy through mitosis regulation. The biologically oriented synthesis yielded several nanomolar inhibitors. The optimized compound CJ2-150 (37) showed a non-ATP competitive allosteric mode of action in a mixed-type inhibition for Aurora B kinase. Molecular docking identified a probable binding mode in the allosteric site "F"and highlighted the key interactions with the protein. We describe the improvement of the inhibitory potency and specificity of the novel scaffold as well as the characterization of the mechanism of action.

P2X3 AND/OR P2X2/3 COMPOUNDS AND METHODS

The present application provides novel compounds and methods for preparing and using these compounds. In one embodiment, the compounds are of the structure of formula (I), wherein R1-R4 are defined herein. In a further embodiment, these compounds are useful in method for regulating one or both of the P2X3 or P2X2/3 receptors. In another embodiment, these compounds are useful for treating pain in patients by administering one or more of the compounds to a patient.

Structure-based drug design of RN486, a potent and selective Bruton's tyrosine kinase (BTK) inhibitor, for the treatment of rheumatoid arthritis

Structure-based drug design was used to guide the optimization of a series of selective BTK inhibitors as potential treatments for Rheumatoid arthritis. Highlights include the introduction of a benzyl alcohol group and a fluorine substitution, each of which resulted in over 10-fold increase in activity. Concurrent optimization of drug-like properties led to compound 1 (RN486) (J. Pharmacol. Exp. Ther. 2012, 341, 90), which was selected for advanced preclinical characterization based on its favorable properties.

SUBSTITUTED IMIDAZOPYRIDINES AND INTERMEDIATES THEREOF

The present invention relates to substituted imidazopyridine compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition for the treatment or prophylaxis of a disease, in particular of a hyper-proliferative and/or angiogenesis disorder, as a sole agent or in combination with other active ingredients.

NOVEL IMIDAZO[1,2-A]PYRIDINE AND IMIDAZO[1,2-B]PYRIDAZINE DERIVATIVES

Imidazo[1,2-a]pyridine and imidazo[1,2-b]pyridazine derivatives which inhibit Btk and are useful for the treatment of auto-immune and inflammatory diseases caused by aberrant B-cell activation, e.g. arthritis.

Versatile templates for the development of novel kinase inhibitors: Discovery of novel CDK inhibitors

A series of four bicyclic cores were prepared and evaluated as cyclin-dependent kinase-2 (CDK2) inhibitors. From the in-vitro and cell-based analysis, the pyrazolo[1,5-a]pyrimidine core (represented by 9) emerged as the superior core for further elaboration in the identification of novel CDK2 inhibitors.

NOVEL IMIDAZOPYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS

In its many embodiments, the present invention provides a novel class of imidazo[1,2-a]pyridine compounds as inhibitors of cyclin dependent kinases, methods of preparing such compounds, pharmaceutical compositions containing one or more such compounds, me